Michael Castagna has bought MNKD on 2 days since Nov 2018

Michael E. Castagna, Pharm.D., MBA, is the Chief Executive Officer and a member of the Board of Directors at MannKind Corporation (NASDAQ: MNKD), a biopharmaceutical company, since May 2017. He joined the company in March 2016 as Chief Commercial Officer. Age 48, Castagna holds a pharmacy degree from the University of the Sciences, a Pharm.D. from Massachusetts College of Pharmacy & Sciences, and an MBA from the Wharton School.(

With over 25 years of experience in healthcare, pharmaceuticals, and biotechnology, Castagna previously served as Vice President of Global Lifecycle Management and Global Commercial Lead for the Biosimilar Business Unit at Amgen (2012–2016), Executive Director of Immunology at Bristol-Myers Squibb (2010–2012 and earlier roles 1997–2005), Vice President & Head of Biopharmaceuticals, North America at Sandoz, and Director roles at Merck, Serono, and Pharmasset. Under his leadership, MannKind achieved significant growth, with 2024 revenue of $285.5 million, net income of $27.6 million, and strong total shareholder return (TSR), turning a $100 investment in 2019 into $498.45 by year-end 2024.(

Written by Perplexity from public sources.